We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Pancreatic Cancer to Be Target of Arizona Research Effort

By LabMedica International staff writers
Posted on 08 Jul 2013
Print article
Two US biomedical organizations based in the state of Arizona have agreed to combine their expertise to discover and develop diagnostic markers for detecting and treating cancer.

The partnership comprises Ventana Medical Systems, Inc. (Tucson, AZ, USA), a member of the Roche Group (Basel, Switzerland) and the Translational Genomics Research Institute (Phoenix, AZ, USA). Ventana Medical Systems manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics, while the Translational Genomics Research Institute is a nonprofit research institute that supports and promotes research on neurological disorders, cancer, and diabetes.

The first target is expected to be pancreatic cancer. This disease, which affects more than 213,000 new patients each year worldwide, has the worst survival rate of any cancer. Fewer than 25% of patients survive more than a year after being diagnosed, and less than 6% are still alive after five years.

"The Translational Genomics Research Institute is on the cutting edge of translational research, where investigators discover the genetic components of disease," said Dr. Jeffrey Trent, president and research director of The Translational Genomics Research Institute. "Our goal is to rapidly translate basic research findings into actionable targets. Partnering with Ventana we hope will accelerate our goal to deliver meaningful discoveries to cancer patients today."

"When a patient is faced with cancer, getting an accurate diagnosis quickly is the most important part of their treatment," said Mara G. Aspinall, president and CEO of Ventana. "As the global leader in tissue-based cancer diagnostics, our strength is moving research into the clinic in order to improve the lives of all patients afflicted with cancer. We are thrilled to be able to pursue this with a partner right in our Arizona backyard."

Related Links:
Ventana Medical Systems, Inc.
The Roche Group
The Translational Genomics Research Institute


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Automated Blood Typing System
IH-500 NEXT
New
Herpes Virus Test
Human Herpes Virus (HHV-6) Real Time PCR Kit
New
Auto-Chemistry Analyzer
CS-1200

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.